Can We Use Nonophthalmic Drug in Ophthalmology? 
Nonophthalmic Drug potential for ophthalmology

Marianne Shahsuvaryan
Yerevan State Medical University, Armenia
E-mail: mar_shah@hotmail.com

ABSTRACT

Progress in ophthalmology is accompanying with nonophthalmic drug use. Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux across cell membranes and affect various intracellular signaling processes, have been long and widely used to treat essential hypertension and certain types of cardiac diseases such as angina pectoris. Among five subtypes of calcium channels, only specific agents for L-type calcium channels have been used as therapeutics. There are potentially multiple biological bases for the protective effect of calcium channel blockers on eye structures. The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that calcium channel blockers may be useful in the prevention and the treatment of different eye diseases.

Key words: calcium channel blockers, glaucoma, retinal degeneration, ocular inflammation, neuroprotective effect, antioxidative action.

Calcium channel blockers, which alter the intracellular calcium concentration by modifying calcium flux across cell membranes and affect various intracellular signaling processes, have been long and widely used to treat essential hypertension and certain types of cardiac diseases such as angina pectoris. Among five subtypes of calcium channels, only specific agents for L-type calcium channels have been used as therapeutics. Calcium antagonists induce vasodilatation at smooth muscle cells and are neuroprotective through their intracellular decrease of $K^+$. Calcium channel blockers generally dilate isolated ocular vessels and increase ocular blood flow in experimental animals, healthy humans, patients with open-angle glaucoma [1-3] and in patients who have vascular diseases in which considerable vascular tone is present. As well, contrast sensitivity in patients with normal tension glaucoma was found ameliorated by calcium channel inhibition[4,5]. Neuroprotective effect of calcium channel blockers against retinal ganglion cell damage under hypoxia was shown by Yamada et al. [6], and also by Garcia-Campos et al. [7]. Apoptosis, genetically programmed mechanism of cell death in which the cell activates a specific set of instructions that lead to the deconstruction of the cell from within, is now understood as a final common pathway for retinitis pigmentosa. Retinitis pigmentosa is an inherited retinal degeneration characterized by nystagmus, ring scotoma, and bone-spicule pigmentation of the retina. Apoptosis can thus be considered as a therapeutic target for retinitis pigmentosa [8,9].

The general consensus is that intracellular concentrations of calcium ion are increased in apoptosis [10-15]. These findings suggest that calcium channel blockers may potentially inhibit ganglion cells and photoreceptor apoptosis in glaucoma and retinitis pigmentosa respectively [3,16]. There are potentially multiple biological bases for the protective effect of calcium channel blockers on eye structures, as was shown above.

The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that calcium channel blockers may be useful in the prevention and the treatment of different eye diseases.

DILTIAZEM

Frasson et al., [17] first reported the effects of D-cis- diltiazem, a benzothiazepin calcium channel antagonist which blocks both cyclic-nucleotide-gated cation channels (CNGC) and voltage-gated calcium channels (VGCC) on photoreceptor protection in rd1 mice, several investigators have reported positive and negative effects of calcium channel blockers on animal models of retinitis pigmentosa [13, 18-24].
The intracellular concentration of calcium ions is subsequently elevated, leading to photoreceptor apoptosis [17]. Sanges et al. [13] demonstrated that systemic administration of D-cis-diltiazem reduced intracellular concentrations of calcium, downregulating calpains and photoreceptor apoptosis in rd1 mice. Direct inhibitory effects of D-cis-diltiazem on L-type VGCC have been reported by Hart et al. [21], and D-cis-diltiazem effectively blocks photoreceptor light damage in mouse models by inhibiting photoreceptor apoptosis [24]. In contrast, L-cis isomer inhibits L-type VGCC similarly to D-cis isomer [25].

The difference in action between D-cis and L-cis-diltiazem on photoreceptor apoptosis suggests that CNGC might also be important for photoreceptor neuroprotection [17]. Despite these studies, however, Takano et al. [23] and Pawlyk et al. [26] found no rescue effects of D-cis-diltiazem on retinal degeneration in rd1 mice, and Bush et al. [18] also reported that D-cis-diltiazem was ineffective for photoreceptor rescue in rhodopsin P23H transgenic rats. The effects of diltiazem on animal models of retinal degeneration remain controversial.

Pasantes-Morales et al. [27] in human study reported that a combination of D-cis-diltiazem, taurin, and vitamin E has beneficial effects on the visual field progression, although the study did not clarify whether diltiazem alone demonstrated beneficial effects. Otori et al. [28] evaluated the effect of diltiazem on inhibition of glutamate-induced apoptotic retinal ganglion cells death and concluded that application of diltiazem do not appear to reduce apoptosis. Investigating the pharmacokinetics of diltiazem after subconjunctival and topical administration in rabbits and effect on wound healing after the creation of conjunctival flaps, Oruc et al. [29] have found that topical and subconjunctival diltiazem successfully penetrated the aqueous humor, but did not appear to affect wound healing.

Based on antioxidative action of calcium channel blockers, which have recently been shown, another therapeutic target is ocular inflammation. Animal study of intraperitoneal injections of either nilvadipine, diltiazem, or vehicle have not found a beneficial inhibitory effect of diltiazem on the pathogenesis of ocular inflammation through the suppression of inflammation-related molecules [30].

NIMODIPINE

Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier due to its high lipid solubility. Its primary action is to reduce the number of open calcium channels in cell membranes, thus restricting influx of calcium ions into cells. Several clinical trials have unequivocally shown that nimodipine is capable of preventing neurological deficits secondary to aneurysmal subarachnoid haemorrhage. The results of the VENUS (Very Early Nimodipine Use in Stroke) study do not support the concept that early nimodipine exerts a beneficial effect in stroke patients [31]. On the other hand oral nimodipine showed an enhanced acute reperfusion if applied within 12 hours of onset of acute stroke [6,31,32]. Yamada et al., [6] in experimental in vitro model revealed that nimodipine have a direct neuroprotective effect against retinal ganglion cells damage related to hypoxia.

Michelson et al., [33] have evaluated the impact of nimodipine on retinal blood flow in double-blind, two-way, crossover study of healthy subjects and found that orally administered at a dosage of 30 mg three times a day nimodipine significantly increases retinal perfusion in healthy subjects. Based on experimental findings Shahsvaryan [34] investigated the efficacy of nimodipine in the prospective comparative clinical interventional study of patients with nonarteritic anterior and posterior optic neuropathy. The author stated that increase in visual acuity was higher in the posterior ischemic neuropathy subgroup than in the anterior ischemic subgroup. Visual field testing during the follow-up also revealed positive transformation of visual field defects size and location, which correlated to visual acuity changes. These encouraging findings need to be confirmed by double-blind study.

Nimodipine has also been shown to significantly inhibit the growth of new vessels in experimental rat model of retinopathy of prematurity [35]. Vascular endothelial growth factor (VEGF) can induce cell proliferation by activating the calcium channel in cell membrane through the influx of calcium increased. Another animal study [36] also have found a beneficial inhibitory effect of nimodipine on proliferative retinopathy by blocking the influx of calcium and expression of VEGF.

The impact of nimodipine on ocular circulation in normal tension glaucoma have been evaluated in many clinical studies.
Piltz et al., [37] have described a performance-corrected improvement in visual field deviation and contrast sensitivity in patients with normal tension glaucoma (NTG) and in control subjects in a prospective, placebo-controlled double-masked study after oral administration of nimodipine (30 mg twice a day). Other authors [38] also stated that a single dose of 30 mg nimodipine normalizes the significantly reduced retinal blood flow in NTG patients with clinical signs of vasospasmic hyperactivity. Luksch et al., [1] have examined the impact of 60 mg nimodipine in NTG patients 2 hours after oral administration. Results disclosed that nimodipine increased the blood flow of the optic nerve head by 18% and improved color-contrast sensitivity. Thus, nimodipine is potentially useful calcium channel blocker for eye disorders treatment due to its high lipid solubility and ability to cross the blood-brain barrier.

**NILVADIPINE**

Recent experimental evidences suggest that Nilvadipine appear to have beneficial effects on different ocular structures. Ogata et al., [39] have evaluated the effects of nilvadipine on retinal blood flow and concluded that this agent may directly and selectively increase retinal tissue blood flow, while having only minimal effect on systemic circulation including arterial blood pressure. Another experimental study conducted by Uemura and Mizota [40] have also advocated the use of nilvadipine for the treatment of glaucoma or other retinal diseases that have some relation to apoptosis, based on claims that nilvadipine has high permeability to retina and neuroprotective effect to retinal cells. Otori et al., [28] in the experimental study of different calcium channel blockers protective effect against glutamate neurotoxicity in purified retinal ganglion cells has found that nilvadipine significantly reduce glutamate-induced apoptosis. Systemic administration of nilvadipine has been shown to be effective for protecting photoreceptors in royal college surgeons rats [20], rd1 mice [23], and heterozygous rd2 (rds) mice [24]. In addition to direct effects of calcium channel blockers on intracellular concentrations of calcium ion in photoreceptor cells, other indirect effects are expected such as increased expression of fibroblast growth factor (FGF) 2 [23] and ciliary neurotrophic factor (CNTF) in the retina [24] and increased choroidal blood flow [2]. In the latest animal study of intraperitoneal injections of nilvadipine Ishida et al., [30] have found a beneficial inhibitory effect of this drug on the pathogenesis of ocular inflammation through the suppression of inflammation-related molecules.

Several clinical trials have shown the effectiveness of nilvadipine in retinitis pigmentosa and glaucoma. Ohguro [41] reported the photoreceptor rescue effects of nilvadipine in a small patient group. Nakazawa et al., [16] expanded his nilvadipine study for RP patients to confirm the results. Although both treated and control groups are still small, authors results have shown significant retardation of the mean deviation (MD) slope as calculated by the central visual field (Humphry Visual Field Analyzer, 10-2 Program) after a mean of 48 months of observation. As these pilot studies are small-sized and cannot completely exclude possible biases, a large-scale, randomized, multicenter human trial of calcium channel blockers is required in order to evaluate their efficacy as therapeutic agents for retinitis pigmentosa.

The potential beneficial impact of nilvadipine on ocular circulation in normal tension glaucoma has been evaluated in different clinical studies. Yamamoto et al., [42] Tomita et al., [43] and Niwa et al., [44] have found that nilvadipine reduces vascular resistance in distal retrobulbar arteries and significantly increases velocity in the central retinal artery in patients with normal tension glaucoma. Tomita et al., [43] also stated that reduced orbital vascular resistance after a 4-week treatment with 2 mg oral nilvadipine consequently increases the optic disc blood flow. Koseki et al., [2] conducted a randomized, placebo-controlled, double-masked, single-center 3-year study of nilvadipine on visual field and ocular circulation in glaucoma with low-normal pressure. No topical ocular hypotensive drugs were prescribed. The authors concluded that nilvadipine (2 mg twice daily) slightly slowed the visual field progression and maintained the optic disc rim, and the posterior choroidal circulation increased over 3 years in patients with open-angle glaucoma with low-normal intraocular pressure. The results of this study add to the growing body of evidence that nilvadipine may be useful for neuroprotection in glaucoma.
Thus, nilvadipine is potentially useful calcium channel blocker for eye disorders treatment due to its hydrophobic nature with high permeability to the central nervous system, including the retina and the highest antioxidant potency among calcium channel blockers.

OTHER CALCIUM CHANNEL BLOCKERS
The experimental study conducted by Oku et al., [45] evaluated the effect of topical iganidipine, a new dihydropyridine derivative calcium channel blocker on the impaired visual evoked potential after endotheolin-1 injection into the vitreous body of rabbits and have advocated iganidipine eyedrops for the treatment of ischemic retinal and optic nerve disorders for the maintenance of visual function. The latest experimental study [46] evaluated a neuroprotective effect of another new calcium channel blocker – lomerizine. The authors stated that lomerizine alleviates secondary degeneration of retinal ganglion cells induced by an optic nerve crush injury in the rat, presumably by improving the impaired axoplasmic circulation in rabbits and on the circulation in the optic nerve head and choroid in healthy volunteers and have found that lomerizine increases blood velocity, and probably blood flow, in the optic nerve head and retina in rabbits, and it also increases blood velocity in the optic nerve head in healthy humans, without significantly altering blood pressure or heart rate.

CONCLUSION
In conclusion, there are potentially multiple biological bases for the therapeutic effect of calcium channel blockers in eye diseases. Taken into account that not all calcium channel blockers are equally effective, the challenge for future laboratory research will be to determine the best type and dosage of calcium channel blockers and also to determine which processes are modulated by these drugs in vivo and therefore are primarily responsible for the apparent beneficial effects observed in the previous studies. Clearly, further observational studies cannot adequately address many unanswered questions. It is time to conduct a randomized controlled trial to provide direct evidence of the effectiveness of specific type nonophthalmic drug - calcium channel blocker in different eye diseases.

REFERENCES
Marianne Shahsuveryan


